Research & Development

The 60° Pharmaceuticals (60P) Malaria Program

According to the World Health Organization’s latest World Malaria Report, there were an estimated 429,000 malaria deaths and 212 million new clinical episodes in 2015.1

Goal of elimination unattainable with current tools

Though therapies exist, the treatment of this potentially fatal disease depends on many factors. These considerations—including increasing numbers of drug-resistant parasites—cause treatment drugs to meet with limited success. Most vaccines are only partially effective, making the goal of elimination unobtainable with current tools.

A grave threat to those deployed in malaria-endemic countries:

  • Armed forces
  • Mining company employees
  • Oil and gas company employees
  • Agriculture and forestry workers
  • NGO employees
  • Contractors and service providers to the above industries

Factors affecting/limiting malaria prevention
The species of malaria parasite potentially causing the infection
Geographic consideration
Compliance with dosing of medication

125 million travelers: U.S. > $250 million market

An estimated 125 million travelers journey through malaria-endemic regions annually. Of those travelers who visit these areas each year, approximately 30,000 become infected with malaria.2 Travelers who are 35 years old or younger, travelers to Africa, those traveling longer than one month, and those who do not follow the prophylactic protocol are at greatest risk for contracting malaria.3,4

New drugs for malaria prevention are needed

Of the several marketed antimalarials available thus far:

  • NONE prevent malaria in all endemic regions for multiple types of malaria
  • NONE have utility against both the disease-causing and latent forms of the parasite

60P: Uniquely positioned to compete in the antimalarial medicine market

  • 60P is developing an 8-aminoquinoline (60P-003) for the prevention of malaria in individuals traveling to endemic areas  
  • 60P has secured research and licensing agreements with the U.S. Army
  • Legacy clinical program includes completed Phase III study
  • Plans for regulatory filings in 2017 and subsequent commercial launch in select markets in 2018
  • Anti-malarial program is supported by in-kind financing from the U.S. Army

The 60P Dengue Program

The frequency of dengue has grown dramatically around the world in recent decades. In fact, the global reach of dengue has more than quadrupled since the 1990s. A recent estimate indicates there are 390 million dengue infections per year.5 In the Americas alone, an estimated 500,000 people with severe dengue require hospitalization each year, with about 2.5% cases leading to death.6 This global economic burden is estimated to exceed US$12 billion annually.7

Grim statistics point to an urgent need

With no current effective therapeutic products against dengue, new treatment and prevention medicine is needed. This additional data provides a larger overview:

  • 2.5 billion people, or 40% of the world’s population, are under the risk of dengue transmission
  • 400 million people infected annually with around 25% being symptomatic
  • Dengue is endemic in at least 100 countries in Asia, the Pacific, the Americas, Africa, and the Caribbean
  • Affected regions have continued to expand due to global warming and globalization

60P: Uniquely positioned to compete in the dengue market

  • 60P is developing an alpha-glucosidase inhibitor (60P001) and a platelet-activating factor receptor antagonist (60P002) for treatment of dengue fever
  • A Phase IB study has been completed on 60P001 by Duke-NUS Medical School and Singapore General Hospital
  • Regulatory/ethical approval in Singapore to conduct Phase II study. Upon successful completion, 60P will seek a strategic partner to complete the clinical program (Phase III) and to commercialize
  • Both products fulfill the U.S. FDA Priority Review Voucher (PRV) criteria
  • This project is supported by a US$3.7 million grant from the Singaporean government (MOH)


Click here to see all products in our pipeline.

References: 1. World Malaria Report 2016. Geneva: World Health Organization; 2016. License: CC BY-NC-SA 3.0 IGO. 2. WHO. Chapter 7: Malaria. In: International travel and health. Geneva: WHO, 2012:148. 3. Provost S, Gagnon S, Lonergan G, et al. Hepatitis A, typhoid and malaria among travelers—surveillance data from Québec (Canada). J Travel Med 2006; 13:219–226. 4. Beherens RH, Curtis CF. Malaria in travelers: epidemiology and prevention. Br Med Bull 1993; 49:363–381. 5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature; 496:504-507. 6. Dengue and Severe Dengue Fact Sheet. Geneva: World Health Organization; April 2017. 7. UPMC-Health Security

Deaths annually in endemic countries from malaria


Travelers to endemic regions per annum


Dengue infections per year


1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036